
Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.

Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.
Founded: 2017
Headquarters: Boston
Focus: Cells-to-software synthetic biology platform for designing and manufacturing biologics and cell/gene therapies
Product highlights: CHO Edge, LV Edge, AAV Edge, Kernel (genetic design software)
Funding: $205,000,000 total (latest listed: Series B on 2023-01-05)
| Company |
|---|
Synthetic biology and biomanufacturing for next-generation therapeutics (biologics, cell and gene therapies).
2017
Biotechnology Research
$4.7M
Reported seed funding amount per press coverage.
“Backed by institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, Fidelity Management & Research Company, Casdin Capital, DCVC, AME Cloud Ventures, KdT Ventures, and Pillar VC.”
Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We're developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics.
We are seeking a Research Associate, High-Throughput Processes (Contractor) to join our team on a 6 month contract in Boston, MA and help push the boundaries of high-throughput cell line engineering for biopharmaceuticals. In this lab-based role you will support day-to-day activities in CHO-based cell line engineering and screening, using high-throughput protocols and laboratory automation. In addition you will contribute to managing the data generated, using our laboratory information management tools. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology startup and help build the future of biological engineering.
About the Role:
About You:
We're fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.